EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Use of, time to, and type of first add‐on anti‐hyperglycaemic therapy to metformin in Australia, 2018–2022

Tamara Y Milder iD, Jialing Lin iD, Sallie-Anne Pearson iD, Jerry R Greenfield iD, Richard O Day iD, Sophie L Stocker iD, Brendon L Neuen, Michael O Falster iD, Juliana de Oliveira Costa iD

British Journal of Clinical Pharmacology · 2025

DOI: 10.1111/bcp.16231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Tamara Y Milder und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australi…. Hauptthemen laut MEDLINE: Metformin, Hypoglycemic Agents, Diabetes Mellitus, Type 2, Drug Therapy, Combination. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Wellcome Trust, National Heart Foundation of Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The aim of this study was to examine contemporary trends in the use of, time to, and type of first add‐on anti‐hyperglycaemic therapy to metformin in Australia.

Methods

We used the dispensing records of a 10% random sample of Pharmaceutical Benefits Scheme (PBS) eligible people. We included people aged 40 years and older initiating metformin from 1 January 2018 to 31 December 2020. Our primary outcome was first add‐on anti‐hyperglycaemic medicine within 2 years of metformin initiation. We analysed time to dispensing of first add‐on therapy. All analyses were stratified by metformin initiation year.

Results

Overall, 38 747 people aged 40 years and older initiated metformin between 2018 and 2020. Approximately one‐third ( n = 12 946) of people received add‐on therapy with the proportion increasing slightly by year of metformin initiation (32.3% in 2018 to 34.8% in 2020). Amongst people with add‐on therapy following metformin initiation, sodium‐glucose cotransporter 2 inhibitor (SGLT2i) use increased from 28.8% (2018) to 35.0% (2020), and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) increased from 3.0% to 9.6%, respectively. Dipeptidyl peptidase‐4 inhibitors and sulfonylureas as first add‐on therapy decreased and insulin remained stable. One‐third of people with add‐on therapy initiated the therapy on the same day metformin was initiated, i.e. initial combination therapy.

Conclusions

Amongst people initiating metformin from 2018 to 2020, there was an increasing proportion of SGLT2i and GLP‐1 RA being used as first add‐on therapy. However, the overall prevalence of add‐on therapy was low. Advocacy to promote add‐on therapy with cardiorenal beneficial medicines is critical to reduce type 2 diabetes morbidity and mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminHypoglycemic AgentsDiabetes Mellitus, Type 2Drug Therapy, CombinationSodium-Glucose Transporter 2 InhibitorsHumansAustraliaFemaleMaleMiddle AgedAgedAdultDipeptidyl-Peptidase IV InhibitorsInsulinPractice Patterns, Physicians'Time FactorsGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

GLP‐1 receptor agonistsSGLT2 inhibitorscombination therapypharmacoepidemiologypharmacotherapytype 2 diabetes

Substanzen

MetforminHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsInsulinGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.
  • Department of Diabetes and Endocrinology, St. Vincent's Hospital, Sydney, Australia.
  • Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Sydney, Australia.
  • Clinical Diabetes, Appetite and Metabolism Laboratory, Garvan Institute of Medical Research, Sydney, Australia.
  • School of Clinical Medicine, UNSW Medicine & Health, St Vincent's Healthcare Clinical Campus, University of New South Wales, Sydney, Australia.
  • School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Australia.

ORCID-Profile: Tamara Y Milder, Jialing Lin, Sallie-Anne Pearson, Jerry R Greenfield, Richard O Day, Sophie L Stocker, Michael O Falster, Juliana de Oliveira Costa

Förderung

  • National Health and Medical Research Council
  • Wellcome Trust
  • National Heart Foundation of Australia
  • NHMRC Emerging Leader Investigator Grant
  • Ramaciotti Foundation Health Investment Grant

Zitieren

APA

Milder, T. Y., Lin, J., Pearson, S. A., Greenfield, J. R., Day, R. O., Stocker, S. L., Neuen, B. L., Falster, M. O., & de Oliveira Costa, J. (2025). Use of, time to, and type of first add‐on anti‐hyperglycaemic therapy to metformin in Australia, 2018–2022. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16231

Vancouver

Milder TY, Lin J, Pearson SA, Greenfield JR, Day RO, Stocker SL, et al. Use of, time to, and type of first add‐on anti‐hyperglycaemic therapy to metformin in Australia, 2018–2022. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.16231

BibTeX
@article{Milder2025,
  author = {Milder, Tamara Y and Lin, Jialing and Pearson, Sallie-Anne and Greenfield, Jerry R and Day, Richard O and Stocker, Sophie L and Neuen, Brendon L and Falster, Michael O and de Oliveira Costa, Juliana},
  title = {Use of, time to, and type of first add‐on anti‐hyperglycaemic therapy to metformin in Australia, 2018–2022},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/bcp.16231}
}
Kostenlos starten →